Truist lowered the firm’s price target on Regeneron (REGN) to $975 from $1,004 and keeps a Buy rating on the shares. The firm notes Regeneron ...

Cantor Fitzgerald upgraded Regeneron (REGN) to Overweight from Neutral with a price target of $695, down from $800, as the analyst took over ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

So while biosimilars have caused some price erosion ... acts as a “reverse DCF,” as it reveals what market assumptions are implied by Regeneron’s valuation. This implies that my base ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

Regeneron Pharmaceuticals's REGN short percent of float has risen 26.83% since its last report. The company recently reported that it has 3.25 million shares sold short, which is 3.12% of all regular ...

The overall negative market sentiment contributed to Regeneron's price movement, emphasizing the impact of macroeconomic factors. Buy, Hold or Sell Regeneron Pharmaceuticals? View our complete ...

Regeneron Pharmaceuticals has a 1 year low of $615.00 and a 1 year high of $1,211.20. The company has a market capitalization of $67.45 billion, a PE ratio of 16.12, a price-to-earnings-growth ...

Regeneron Pharmaceuticals has announced the U.S. FDA's acceptance for Priority Review of the supplemental Biologics License Application for EYLEA HD (aflibercept) Injection 8 mg, which, if ...

Baird lowered their target price on Regeneron Pharmaceuticals from $ ... The company has a market cap of $69.34 billion, a price-to-earnings ratio of 16.57, a PEG ratio of 2.34 and a beta of ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for treating adults and adolescents aged 12 and older with chronic spontaneous urticaria (CSU) who continue to ...